Navigation Links
Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
Date:2/2/2011

AUSTIN, Texas, Feb. 2, 2011 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of breast cancer and to the measurement of the biomarkers by mass spectrometry.

"The notice of allowance for this breast cancer biomarker patent is additional validation of our approach to intellectual property protection. We view the increasing breadth of our patent portfolio as a significant corporate asset," said Gail S. Page, CEO and Chairperson of the Board of Directors of Vermillion.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Austin, Texas. Additional information about Vermillion can be found on the Web at www.vermillion.com.

Forward-Looking Statement

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.  


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion Announces Issuance of European Patent
2. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
3. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
4. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
5. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
6. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
7. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
8. Vermillion Announces Receipt of NASDAQ Panel Decision
9. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
10. International Isotopes Inc. Announces a Shareholder Conference Call for February 7, 2011
11. Advanced Health Media Company Announces Renee DeFranco as Senior Vice President - Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... KS. (PRWEB) , ... April 28, 2017 , ... ... contract research organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay ... validated a 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional ...
(Date:4/27/2017)... ... , ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive ... a rare devastating genetic disease that leads to a sudden and rapid loss of ... patients carrying 11778, 14484 and 3460 mutations and having experienced the onset of symptoms ...
(Date:4/27/2017)... California (PRWEB) , ... April 27, 2017 , ... ... new infographic explaining why mass flow controllers based on capillary thermal mass flow ... industrial gas mass flow control applications. Over 80% of all industrial processes—such ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
Breaking Biology Technology:
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , ... Well Made Simple," and 23andMe , the leading ... better food choices.  Zipongo can now provide customers with ... preferences, health goals and biometrics, but also genetic markers ... choices. Zipongo,s personalized food decision support platform ...
Breaking Biology News(10 mins):